Breaking News Instant updates and real-time market news.

INCY

Incyte

$66.69

-0.3 (-0.45%)

12:45
05/17/18
05/17
12:45
05/17/18
12:45

Incyte has a conference call hosted by JPMorgan

JPMorgan Analyst Kasimov will host a conference call with CEO Herve Hoppenot on May 17 at 1 pm.

  • 17

    May

  • 12

    Jun

INCY Incyte
$66.69

-0.3 (-0.45%)

04/26/18
PIPR
04/26/18
NO CHANGE
Target $125
PIPR
Overweight
Nektar data at ASCO to confirm already positive data, says Piper Jaffray
Following Incyte's (INCY) epacadostat failure and the recent, "relatively underwhelming" Bristol-Myers (BMY) lung cancer dataset, there has been a negative shift in investor sentiment towards pure immuno-oncology combination approaches, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The analyst believes there is now increased scrutiny towards uncontrolled trials with low patient numbers, and thinks investors will require a more significant margin of improvement when compared to standard of care until definitively proven in Phase III. As such, he expects investors to be increasingly critical of early IO combination data. Nevertheless, he continues to believe that Nektar Therapeutics' (NKTR) NKTR-214 data at ASCO in early June will be "confirmatory of the already positive data in existing tumor types and supportive of new indications." He keeps an Overweight rating on Nektar shares with a $125 price target.
04/24/18
WBLR
04/24/18
NO CHANGE
WBLR
Incyte may trade flat or slightly up on panel outcome, says William Blair
William Blair analyst Y. Katherine Xu views yesterday's FDA panel, supporting approval of baricitinib at the 2 mg dose but voting against the 4 mg dose, as largely in line with expectations given the doubts raised in the briefing documents and during the panel discussion. Based on the panel's recommendation, the analyst maintains her 90% probability of success for baricitinib 2 mg to be approved in the United States by its action date in June. While an approval will be positive, the narrower label and restriction to the lower dose may limit baricitinib's market share, Xu tells investors in a research note. She believes Incyte (INCY) shares may trade flat or slightly positive on this outcome. The stock in premarket trading us down 4% to $65.60. Xu views the baricitinib panel outcome as a "slight net positive" to upadacitinib of AbbVie (ABBV).
04/24/18
JMPS
04/24/18
NO CHANGE
JMPS
JMP says baricitinib represents 'relatively small' part of Incyte value
After the majority of an FDA advisory committee members voted that the 2mg dose of baricitinib demonstrated efficacy and had a cleaner safety profile compared to the higher dose and also voted against recommending approval of the 4mg dose, JMP Securities analyst Liisa Bayko said she believes the 4mg dose of baricitinib "has a bleak future." However, she said the value of baricitinib is a "relatively small" part of the overall value of Incyte shares. Bayko, who previously had an Outperform rating and $145 price target on Incyte, noted that her rating and price target remain under review.
04/23/18
RBCM
04/23/18
NO CHANGE
RBCM
Outperform
Incyte AdCom meeting going more favorably than docs suggested, says RBC Capital
RBC Capital analyst Brian Abrahams said the FDA advisory committee meeting for baricitinib, a rheumatoid arthritis treatment developed by Incyte (INCY) and submitted for review by Eli Lilly (LLY), seems "considerably less negative" than the briefing documents for the meeting had suggested. He sees the tone of the panel and the panelist Q&A suggesting a high likelihood that baricitinib will be approved, with the potential still existing that even a 4mg version could be approved in some form. Abrahams has an Outperform rating and $75 price target on Incyte shares.

TODAY'S FREE FLY STORIES

MTEM

Molecular Templates

$7.02

0.34 (5.09%)

16:17
05/25/18
05/25
16:17
05/25/18
16:17
Syndicate
Breaking Syndicate news story on Molecular Templates »

Molecular Templates files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
05/25/18
05/25
16:17
05/25/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$272.22

-0.65 (-0.24%)

, USO

United States Oil Fund

$13.68

-0.605 (-4.24%)

16:16
05/25/18
05/25
16:16
05/25/18
16:16
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 2.1K…

SPY

SPDR S&P 500 ETF Trust

$272.22

-0.65 (-0.24%)

USO

United States Oil Fund

$13.68

-0.605 (-4.24%)

GLD

SPDR Gold Trust

$123.21

-0.4 (-0.32%)

FXE

Euro Currency Trust

$111.98

-0.62 (-0.55%)

FXC

CurrencyShares Canadian Dollar Trust

$76.07

-0.37 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
05/25/18
05/25
16:16
05/25/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$102.20

0.1 (0.10%)

16:15
05/25/18
05/25
16:15
05/25/18
16:15
Periodicals
Disney cuts opening weekend sales forecast for 'Solo', Bloomberg says »

Disney cut its domestic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMSA

Fairmount Santrol

$5.51

-0.26 (-4.51%)

16:11
05/25/18
05/25
16:11
05/25/18
16:11
Hot Stocks
Fairmount Santrol, Unimin receive final merger approval »

Fairmount Santrol and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMBL

RumbleON

$4.88

0.16 (3.39%)

16:10
05/25/18
05/25
16:10
05/25/18
16:10
Syndicate
Breaking Syndicate news story on RumbleON »

RumbleON files $20M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAVS

Ageagle Aerial Systems

$2.25

0.04 (1.81%)

16:10
05/25/18
05/25
16:10
05/25/18
16:10
Syndicate
Breaking Syndicate news story on Ageagle Aerial Systems »

Ageagle Aerial Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCI

Appliance Recycling

$0.82

(0.00%)

16:08
05/25/18
05/25
16:08
05/25/18
16:08
Hot Stocks
Appliance Recycling receives noncompliance notice from NASDAQ »

Appliance Recycling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIT

CIT Group

$51.62

-1.13 (-2.14%)

16:06
05/25/18
05/25
16:06
05/25/18
16:06
Hot Stocks
CIT Group names Marisa Harney chief risk officer »

CIT Group announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRVG

Trivago

$4.81

(0.00%)

16:04
05/25/18
05/25
16:04
05/25/18
16:04
Hot Stocks
Breaking Hot Stocks news story on Trivago »

Par Investment Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGLN

Magellan Health

$90.05

1.1 (1.24%)

15:56
05/25/18
05/25
15:56
05/25/18
15:56
Hot Stocks
Magellan Health boosts stock repurchase authorization to $400M »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

LPI

Laredo Petroleum

$8.60

-0.765 (-8.17%)

15:50
05/25/18
05/25
15:50
05/25/18
15:50
Options
Notable put spread in Laredo Petroleum on a rough week for shares »

Notable put spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$14.57

-0.025 (-0.17%)

15:42
05/25/18
05/25
15:42
05/25/18
15:42
Periodicals
GE lighting business, pursued by multiple suitors, could fetch $1B, FBN says »

Charles Gasparino of Fox…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$37.03

0.15 (0.41%)

15:40
05/25/18
05/25
15:40
05/25/18
15:40
Options
AstraZeneca call buyer opens position 4% above spot »

AstraZeneca call buyer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

HEDJ

WisdomTree Europe Hedged Equity Fund

$66.46

-0.24 (-0.36%)

15:30
05/25/18
05/25
15:30
05/25/18
15:30
Options
Wisdom Tree Europe Hedged Equity Fund attracts put buying »

Wisdom Tree Europe Hedged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATUS

Altice USA

$18.43

-0.12 (-0.65%)

15:29
05/25/18
05/25
15:29
05/25/18
15:29
Conference/Events
Altice USA management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

CLX

Clorox

$122.59

2.89 (2.41%)

15:25
05/25/18
05/25
15:25
05/25/18
15:25
Options
Clorox call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

QCOM

Qualcomm

$59.67

0.57 (0.96%)

, NXPI

NXP Semiconductors

$116.47

5.03 (4.51%)

15:22
05/25/18
05/25
15:22
05/25/18
15:22
Periodicals
Dealreporter: Qualcomm given ok to resume NXP talks with China, Bloomberg says »

Bloomberg cites…

QCOM

Qualcomm

$59.67

0.57 (0.96%)

NXPI

NXP Semiconductors

$116.47

5.03 (4.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OA

Orbital ATK

$133.80

0.06 (0.04%)

15:20
05/25/18
05/25
15:20
05/25/18
15:20
Hot Stocks
Orbital ATK reports options awarded for two more weather satellites for NOAA »

Orbital ATK announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
05/25/18
05/25
15:17
05/25/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADRNY

Ahold Delhaize

$0.00

(0.00%)

15:16
05/25/18
05/25
15:16
05/25/18
15:16
Conference/Events
Ahold Delhaize management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
05/25/18
05/25
15:16
05/25/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKY

Skyline

$30.20

-0.31 (-1.02%)

15:10
05/25/18
05/25
15:10
05/25/18
15:10
Conference/Events
Skyline to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBOE

Cboe Global Markets

$102.62

-0.13 (-0.13%)

15:05
05/25/18
05/25
15:05
05/25/18
15:05
Options
CBOE Holdings call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.